i've been running a full on kde4 session on my desktop for a while now. i'm using amarok2 to play my music even. the interface is still very unfinished in the new amarok as they are still in early days development wise, but already the shape of things coming can be seen and i have to say i'm pretty excited about it.
kwin composite is getting better and better, and the window management plugins rock, but it is still a bit too slow for me to deal with. at the recent rate of improvement, though, i hope that will be a different story in the near future =)
for everything else, i'm using kde3 apps with no problems whatsoever. they start up and run fast and well and ... it's all very unexciting. which is good news: this means that for apps not ready for 4.0 we can continue to use the kde3 versions.
oxygen is coming together very nicely these days, too. Girish @ TT fixed a stylesheet related bug that was plaguing lineedits, and the patch is already in qt-copy .. they look much better now. =) i'm not a fan of the red colour used for keyboard focus, but boy are things coming together day by day ... e.g. the tabs in konsole are looking whole again.
still bugs and performance issues around, but i'm very comfortable now in the kde4 session. this is great news given how close we are to a release =)
switching gears now:
Microsoft's bribery attempt in Nigeria has been headed off ... for now at least. that means 17,000 more KDE systems (with how many users per system, i wonder?) via Mandriva. and if Nigeria can keep Microsoft's money slut paws off of things, it looks like that will expand to 100k units with time.
another interesting point from that same article: two out of the three operating system Intel has certified on the classmate PC default to KDE. the third OS? Windows XP.
to Microsoft: our market share will continue to grow. your money and lack of ethics can't stop that. so maybe it's time you stop fighting and start cooperating? i know many of your more technical people think exactly that ... it's time to get your upper management on the new meds. as the saying goes, "to cross the river, do not fight the river".